Cytokinetics Investors Alert: Deadline to Seek Lead Plaintiff is November 17, 2025.

Faruqi & Faruqi LLP is investigating potential claims against Cytokinetics, a biopharmaceutical company. The investigation focuses on the company's securities between December 27, 2023, and May 6, 2025. Investors who suffered losses during this period are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The deadline to seek lead plaintiff status is November 17, 2025.

New York, NY - Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation into potential claims against Cytokinetics, Incorporated (NASDAQ: CYTK). The investigation focuses on the company's securities between December 27, 2023, and May 6, 2025, during which time investors are alleged to have suffered significant losses.

Faruqi & Faruqi partner Josh Wilson has encouraged investors who purchased or acquired Cytokinetics' securities during this period to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. Investors are reminded that the deadline to seek lead plaintiff status in a potential securities class action lawsuit is November 17, 2025 SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics^[1].

The investigation centers on allegations that Cytokinetics made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten. Specifically, the company represented that it expected approval from the U.S. Food and Drug Administration (FDA) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, but failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy (REMS) that could delay the regulatory process SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics^[1].

On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants' awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics^[1].

As a result of these false and misleading statements, class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was revealed. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics^[1].

Investors who wish to serve as lead plaintiff in this class action must petition the Court by November 17, 2025. The ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics^[1].

In addition to the class action lawsuit, Cytokinetics is scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum^[2].